Cargando…
Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma
MT-3724, a novel engineered toxin body comprised of an anti-CD20 single-chain variable fragment genetically fused to Shiga-like Toxin A subunit, is capable of binding to and internalizing against CD20, inducing cell killing via permanent ribosomal inactivation. This study evaluated MT-3724 in patien...
Autores principales: | Hamlin, Paul A., Musteata, Vasile, Park, Steven I., Burnett, Christine, Dabovic, Kristina, Strack, Thomas, Williams, Eric T., Anand, Banmeet S., Higgins, Jack P., Persky, Daniel O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981212/ https://www.ncbi.nlm.nih.gov/pubmed/36875713 http://dx.doi.org/10.1158/2767-9764.CRC-22-0056 |
Ejemplares similares
-
The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma
por: Huang, Shengjian, et al.
Publicado: (2018) -
Relapsed/Refractory Hodgkin Lymphoma
por: Sheikh, Semira, et al.
Publicado: (2018) -
Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015) -
New agents in relapsed/refractory Hodgkin's lymphoma()
por: Biasoli, Irene, et al.
Publicado: (2017) -
Hodgkin Lymphoma Mimicking Osteomyelitis
por: Majeed, Aneela, et al.
Publicado: (2017)